Current opinion in otolaryngology & head and neck surgery · 2025
Cochlear gene therapy for otoferlin-related hearing loss.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lustig Lawrence
Аннотация
PURPOSE OF REVIEW: There are currently five groups internationally involved in human clinical gene therapy trials for otoferlin-associated hearing loss. This includes (in alphabetical order) the Eye and ENT Hospital Fudan University (China), Lilly-Akouos (USA), Otovia (China), Regeneron (USA), and Sensorion (France). This review summarizes early work that led to these efforts and highlights early published data on clinical outcomes.
RECENT FINDINGS: While published outcomes are currently limited, data emerging from each of these clinical trials is highly consistent. Using a dual vector approach to reconstitute full length Otoferlin, all groups report varying degrees of hearing improvement following cochlear gene therapy, with some cases of hearing restoration to normal levels. Recent data suggests that improvement is not limited only to young children but also adolescents and even young adults in some cases. The treatments all appear safe with limited adverse effects associated with the therapies reported.
SUMMARY: Gene therapy for otoferlin-related deafness appears highly successful in most cases with limited reported adverse effects or outcomes. This success will undoubtably usher in a new era of gene therapy for other forms of genetic deafness.
RECENT FINDINGS: While published outcomes are currently limited, data emerging from each of these clinical trials is highly consistent. Using a dual vector approach to reconstitute full length Otoferlin, all groups report varying degrees of hearing improvement following cochlear gene therapy, with some cases of hearing restoration to normal levels. Recent data suggests that improvement is not limited only to young children but also adolescents and even young adults in some cases. The treatments all appear safe with limited adverse effects associated with the therapies reported.
SUMMARY: Gene therapy for otoferlin-related deafness appears highly successful in most cases with limited reported adverse effects or outcomes. This success will undoubtably usher in a new era of gene therapy for other forms of genetic deafness.